PharmaTelevision - BioBDx: Byron Hewett explains their mission to change the way that ADHD is managed using their Quotient system.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BioBDx: Byron Hewett explains their mission to change the way that ADHD is managed using their Quotient system.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Byron Hewett, Executive Chairman of BioBDx.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Quotient ADHD system in assessment of ADHD

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston. On this show I have Byron Hewett, who is the CEO and Chairman of a company called BioBDx , welcome to the show.

Byron Hewett:

Thank you, glad to be here.

Fintan Walton:

Good. Now tell me little bit about BioBDx , what sort of organization it is?

Byron Hewett:

We're private company about 20 employees, venture backed. We licensed the technology from McLean Hospital which is part of the Harvard Partners System here in town and we've been commercializing the technology over the last two or three-years.

Fintan Walton:

Okay, and that technology is applied into a specific product that's called Quotient-ADHD?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Byron Hewett

Executive Chairman

Byron Hewett currently serves as Executive Chairman of BioBehavioral Diagnostics (BioBDx) . Byron Hewett joined BioBehavioral Diagnostics in November, 2008 as executive chairman. Mr. Hewett has served on the board of directors since July 2006. From 2004 to 2008, Mr. Hewett served as chief executive officer, president, and a director at Immunicon Corporation. From 2002-2004, he served as senior vice president of sales and marketing and general manager, North America for Qiagen, Inc. where he led commercial North American operations. Mr. Hewett has worked in healthcare and life science companies for more than 20 years in general management, strategy formulation, business development and sales and marketing with firms including Bayer Diagnostics, Chiron Diagnostics, Biocircuits Corporation, Stericycle, Inc., and Abbott Laboratories. Mr. Hewett received a Masters in Management degree from Northwestern University's J.L. Kellogg Graduate School of Management and a Bachelors of Science degree from the University of Virginia's McIntire School of Commerce.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

BioBehavioral Diagnostics (BioBDx)

BioBehavioral Diagnostics (BioBDx) manufactures and markets the Quotient-ADHD-System, a tool that aids in the objective and accurate assessment of ADHDsymptoms. BioBDx are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD. BioBDx 's vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine. Founded in 2006, BioBDx is a privately held company.